MPH Health Care AG: result Q1-2021

EBIT amounts to EUR 22.5 million in Q1. Equity (net asset value) rises to EUR 223.4 million, corresponding to EUR 52.19 per share.

In the first quarter of 2021, MPH Health Care AG (ISIN: DE000A289V03) benefited from the recovery of the stock market prices of its listed investments and achieved an operating result (EBIT) according to IFRS of EUR 22.5 million (same period previous year: EUR -88.4 million).

Equity increased by 11.0% to EUR 223.4 million (31.12.2020: EUR 201.3 million). Net asset value (NAV) per share increased accordingly from EUR 47.01 to EUR 52.19. The equity ratio as at 31.03.2021 increased slightly to 96.0% (31.12.2020: 95.5%).

The investment M1 Kliniken AG had a successful start into the year 2021 with a significant increase in revenues and earnings in the two business segments "Beauty" and "Trade". Consolidated revenue rose to around EUR 81 million in the first quarter of 2021 (previous year EUR 23 million) and EBITDA to EUR 4.0 million (previous year EUR 1.4 million).

In the Beauty segment, the new year had a slow start (due to the ongoing Corona pandemic) with treatment figures around 20% below the previous year. However, by the end of the quarter, M1 was back to historic peak daily sales and continued to grow. In Q1-2021 as a whole, almost 81 thousand treatments were carried out compared to 73 thousand treatments in the same quarter of the previous year. By the end of May 2021, four new specialist centers had already been opened in the German market. According to current planning, a total of 50 M1 specialist centers are planned by the end of 2021, with further locations also opening in foreign markets.

In the trading segment, the operational optimization of the business activities of HAEMATO AG continued, which was able to report an increase in turnover in the past quarter compared to the previous year. In the process, HAEMATO AG was able to significantly improve its profitability. The share price of M1 Kliniken AG improved from 9.24 euros on 31 December 2020 to 10.85 euros on 31 March 2021.

Our second listed investment CR Capital AG (formerly CR Capital Real Estate AG) was also able to continue on its successful path in 2021 - almost unaffected by the COVID-19 pandemic - and continued to grow profitably. In the first three months, CR Capital was already able to notarially sell 161 residential units with a sales volume of approx. EUR 54 million in the projects Rousseau Park in the Berlin suburbs and Leipzig-Schkeuditz via participation Terrabau. The share price of CR Capital AG has increased from EUR 30.50 on 31 December 2020 to EUR 32.50 on 31 March 2021.

With an increasing easing of the Corona restrictions due to rising vaccination rates and falling case numbers, we are confident about the further development of our investments. All M1 Med Beauty locations in Germany and abroad have been reopened in the meantime, HAEMATO AG is making an important contribution to the Corona pandemic with the sale of medical products for Covid-19 diagnostics, and CR Capital AG has so far been able to record a continually strong demand for affordable residential real estate.

Due to the ongoing Corona pandemic, MPH Health Care AG will make use of the option to invite shareholders to the company's Annual General Meeting scheduled for 15 July 2021 with a shortened notice period of 21 days.